241
Participants
Start Date
July 15, 2016
Primary Completion Date
August 19, 2019
Study Completion Date
December 9, 2019
Fimasartan or Fimasartan/Hydrochlorothiazide
The treatment in this clinical study starts with fimasartan 30 mg; if blood pressure is not controlled (siSBP ≥ 140 mmHg or siDBP ≥ 90 mmHg), the dose is escalated once gradually, and then a diuretic combination is administered. The escalation of dose and administration of diuretic combination are decided after checking blood pressure 4 weeks after the administration of each investigational product.
Perindopril or Perindopril/Indapamide
The treatment in this clinical study starts with penrindopril 2.5 mg; if blood pressure is not controlled (siSBP ≥ 140 mmHg or siDBP ≥ 90 mmHg), the dose is escalated once gradually, and then a diuretic combination is administered. The escalation of dose and administration of diuretic combination are decided after checking blood pressure 4 weeks after the administration of each investigational product.
Seoul National University Bundang, Seoul
Lead Sponsor
Boryung Pharmaceutical Co., Ltd
INDUSTRY